25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Protalix Biotherapeutics Inc
Buy, Hold or Sell?

Let's analyze Protalix together

I guess you are interested in Protalix Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Protalix Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Protalix Biotherapeutics Inc

I send you an email if I find something interesting about Protalix Biotherapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Protalix (30 sec.)










1.2. What can you expect buying and holding a share of Protalix? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.40
Expected worth in 1 year
$0.34
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$-0.06
Return On Investment
-3.1%

For what price can you sell your share?

Current Price per Share
$1.83
Expected price per share
$1.54 - $1.8301
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Protalix (5 min.)




Live pricePrice per Share (EOD)
$1.83
Intrinsic Value Per Share
$0.86 - $3.31
Total Value Per Share
$1.26 - $3.71

2.2. Growth of Protalix (5 min.)




Is Protalix growing?

Current yearPrevious yearGrowGrow %
How rich?$32.4m$16.9m$14.1m45.6%

How much money is Protalix making?

Current yearPrevious yearGrowGrow %
Making money-$2.4m$2.6m-$5m-210.5%
Net Profit Margin-44.6%-9.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Protalix (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#486 / 939

Most Revenue
#268 / 939

Most Profit
#322 / 939

Most Efficient
#383 / 939
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Protalix?

Welcome investor! Protalix's management wants to use your money to grow the business. In return you get a share of Protalix.

First you should know what it really means to hold a share of Protalix. And how you can make/lose money.

Speculation

The Price per Share of Protalix is $1.83. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Protalix.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Protalix, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.40. Based on the TTM, the Book Value Change Per Share is $-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Protalix.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.042.2%-0.03-1.8%0.031.6%-0.03-1.7%-0.05-2.9%
Usd Book Value Change Per Share0.010.6%-0.01-0.8%0.158.4%0.073.7%0.031.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.6%-0.01-0.8%0.158.4%0.073.7%0.031.4%
Usd Price Per Share1.02-1.31-1.78-2.05-1.45-
Price to Earnings Ratio6.40--3.46--8.93-13.77-6.72-
Price-to-Total Gains Ratio90.79--730.75--0.59--123.59--65.64-
Price to Book Ratio2.55-3.15-37.96-30.63-15.28-
Price-to-Total Gains Ratio90.79--730.75--0.59--123.59--65.64-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.83
Number of shares546
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.07
Usd Total Gains Per Share-0.010.07
Gains per Quarter (546 shares)-7.8037.17
Gains per Year (546 shares)-31.19148.68
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-31-410149139
20-62-720297288
30-94-1030446437
40-125-1340595586
50-156-1650743735
60-187-1960892884
70-218-227010411033
80-249-258011891182
90-281-289013381331
100-312-320014871480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%7.033.00.017.5%10.0101.00.09.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%9.011.00.045.0%13.027.00.032.5%24.082.05.021.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.0111.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%9.011.00.045.0%13.027.00.032.5%24.082.05.021.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Protalix Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.011-0.014+227%0.153-93%0.068-83%0.026-57%
Book Value Per Share--0.3990.412-3%0.199+101%-0.022+106%-0.290+173%
Current Ratio--1.9761.555+27%2.000-1%1.486+33%2.340-16%
Debt To Asset Ratio--0.4730.608-22%0.824-43%1.069-56%1.361-65%
Debt To Equity Ratio--0.8981.658-46%16.897-95%24.921-96%13.458-93%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--81124409.36088833716.340-9%118662030.285-32%115944877.733-30%56279346.791+44%
Eps--0.040-0.034+184%0.029+36%-0.031+179%-0.053+233%
Ev To Ebitda Ratio--4.536-4.277+194%-12.958+386%-6.909+252%-3.060+167%
Ev To Sales Ratio--1.1292.697-58%2.291-51%2.548-56%1.484-24%
Free Cash Flow Per Share--0.0490.023+114%-0.028+157%-0.045+191%-0.056+213%
Free Cash Flow To Equity Per Share---0.202-0.040-80%0.139-245%0.002-8494%-0.031-85%
Gross Profit Margin---4.5131.750-358%4.273-206%0.735-714%0.921-590%
Intrinsic Value_10Y_max--3.306--------
Intrinsic Value_10Y_min--0.864--------
Intrinsic Value_1Y_max---0.068--------
Intrinsic Value_1Y_min---0.172--------
Intrinsic Value_3Y_max--0.101--------
Intrinsic Value_3Y_min---0.297--------
Intrinsic Value_5Y_max--0.636--------
Intrinsic Value_5Y_min---0.177--------
Market Cap134749488.000+39%82841409.36098209716.340-16%140247280.285-41%153146127.733-46%107547221.791-23%
Net Profit Margin--0.180-0.446+348%-0.097+154%-0.362+301%-2.621+1555%
Operating Margin--0.231-0.402+274%-0.020+109%-0.257+211%-1.611+799%
Operating Ratio--0.7781.447-46%1.037-25%1.272-39%2.810-72%
Pb Ratio4.582+44%2.5543.147-19%37.956-93%30.630-92%15.275-83%
Pe Ratio11.482+44%6.400-3.461+154%-8.928+240%13.771-54%6.723-5%
Price Per Share1.830+44%1.0201.308-22%1.783-43%2.050-50%1.446-29%
Price To Free Cash Flow Ratio9.248+44%5.1543.929+31%-4.214+182%-4.199+181%-3.179+162%
Price To Total Gains Ratio162.885+44%90.789-730.753+905%-0.588+101%-123.591+236%-65.645+172%
Quick Ratio--1.2221.360-10%1.489-18%1.452-16%2.079-41%
Return On Assets--0.053-0.024+145%0.021+152%-0.030+156%-0.063+220%
Return On Equity--0.100-0.078+178%-0.665+766%-1.299+1402%-0.563+665%
Total Gains Per Share--0.011-0.014+227%0.153-93%0.068-83%0.026-57%
Usd Book Value--32437000.00031093250.000+4%16904000.000+92%-1034850.000+103%-21054725.000+165%
Usd Book Value Change Per Share--0.011-0.014+227%0.153-93%0.068-83%0.026-57%
Usd Book Value Per Share--0.3990.412-3%0.199+101%-0.022+106%-0.290+173%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--81124409.36088833716.340-9%118662030.285-32%115944877.733-30%56279346.791+44%
Usd Eps--0.040-0.034+184%0.029+36%-0.031+179%-0.053+233%
Usd Free Cash Flow--4018000.0001792749.750+124%-2159000.000+154%-3324450.050+183%-4122225.025+203%
Usd Free Cash Flow Per Share--0.0490.023+114%-0.028+157%-0.045+191%-0.056+213%
Usd Free Cash Flow To Equity Per Share---0.202-0.040-80%0.139-245%0.002-8494%-0.031-85%
Usd Market Cap134749488.000+39%82841409.36098209716.340-16%140247280.285-41%153146127.733-46%107547221.791-23%
Usd Price Per Share1.830+44%1.0201.308-22%1.783-43%2.050-50%1.446-29%
Usd Profit--3236000.000-2401500.000+174%2654000.000+22%-2232950.000+169%-3868900.000+220%
Usd Revenue--17959000.00011416750.000+57%15906250.000+13%13366000.000+34%9317075.000+93%
Usd Total Gains Per Share--0.011-0.014+227%0.153-93%0.068-83%0.026-57%
 EOD+4 -4MRQTTM+24 -14YOY+21 -175Y+23 -1510Y+24 -14

3.3 Fundamental Score

Let's check the fundamental score of Protalix Biotherapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1511.482
Price to Book Ratio (EOD)Between0-14.582
Net Profit Margin (MRQ)Greater than00.180
Operating Margin (MRQ)Greater than00.231
Quick Ratio (MRQ)Greater than11.222
Current Ratio (MRQ)Greater than11.976
Debt to Asset Ratio (MRQ)Less than10.473
Debt to Equity Ratio (MRQ)Less than10.898
Return on Equity (MRQ)Greater than0.150.100
Return on Assets (MRQ)Greater than0.050.053
Total8/10 (80.0%)

3.4 Technical Score

Let's check the technical score of Protalix Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5067.275
Ma 20Greater thanMa 501.740
Ma 50Greater thanMa 1001.484
Ma 100Greater thanMa 2001.254
OpenGreater thanClose1.780
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Protalix Biotherapeutics Inc

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Fundamental data was last updated by Penke on 2024-12-18 15:44:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Protalix earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Protalix to the Biotechnology industry mean.
  • A Net Profit Margin of 18.0% means that $0.18 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Protalix Biotherapeutics Inc:

  • The MRQ is 18.0%. The company is making a huge profit. +2
  • The TTM is -44.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ18.0%TTM-44.6%+62.7%
TTM-44.6%YOY-9.7%-34.9%
TTM-44.6%5Y-36.2%-8.4%
5Y-36.2%10Y-262.1%+225.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.0%-108.0%+126.0%
TTM-44.6%-216.4%+171.8%
YOY-9.7%-207.4%+197.7%
5Y-36.2%-346.2%+310.0%
10Y-262.1%-462.2%+200.1%
4.3.1.2. Return on Assets

Shows how efficient Protalix is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Protalix to the Biotechnology industry mean.
  • 5.3% Return on Assets means that Protalix generated $0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Protalix Biotherapeutics Inc:

  • The MRQ is 5.3%. Using its assets, the company is efficient in making profit. +1
  • The TTM is -2.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ5.3%TTM-2.4%+7.6%
TTM-2.4%YOY2.1%-4.4%
TTM-2.4%5Y-3.0%+0.6%
5Y-3.0%10Y-6.3%+3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3%-11.6%+16.9%
TTM-2.4%-11.9%+9.5%
YOY2.1%-11.2%+13.3%
5Y-3.0%-12.6%+9.6%
10Y-6.3%-14.1%+7.8%
4.3.1.3. Return on Equity

Shows how efficient Protalix is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Protalix to the Biotechnology industry mean.
  • 10.0% Return on Equity means Protalix generated $0.10 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Protalix Biotherapeutics Inc:

  • The MRQ is 10.0%. Using its investors money, the company is less efficient in making profit.
  • The TTM is -7.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ10.0%TTM-7.8%+17.8%
TTM-7.8%YOY-66.5%+58.7%
TTM-7.8%5Y-129.9%+122.1%
5Y-129.9%10Y-56.3%-73.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.0%-14.3%+24.3%
TTM-7.8%-15.9%+8.1%
YOY-66.5%-14.7%-51.8%
5Y-129.9%-18.1%-111.8%
10Y-56.3%-19.1%-37.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Protalix Biotherapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Protalix is operating .

  • Measures how much profit Protalix makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Protalix to the Biotechnology industry mean.
  • An Operating Margin of 23.1% means the company generated $0.23  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Protalix Biotherapeutics Inc:

  • The MRQ is 23.1%. The company is operating efficient. +1
  • The TTM is -40.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ23.1%TTM-40.2%+63.3%
TTM-40.2%YOY-2.0%-38.2%
TTM-40.2%5Y-25.7%-14.5%
5Y-25.7%10Y-161.1%+135.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.1%-201.9%+225.0%
TTM-40.2%-313.2%+273.0%
YOY-2.0%-217.2%+215.2%
5Y-25.7%-373.9%+348.2%
10Y-161.1%-475.9%+314.8%
4.3.2.2. Operating Ratio

Measures how efficient Protalix is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.78 means that the operating costs are $0.78 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Protalix Biotherapeutics Inc:

  • The MRQ is 0.778. The company is efficient in keeping operating costs low. +1
  • The TTM is 1.447. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.778TTM1.447-0.669
TTM1.447YOY1.037+0.411
TTM1.4475Y1.272+0.175
5Y1.27210Y2.810-1.539
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7782.183-1.405
TTM1.4473.220-1.773
YOY1.0373.263-2.226
5Y1.2724.651-3.379
10Y2.8106.410-3.600
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Protalix Biotherapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Protalix is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.98 means the company has $1.98 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Protalix Biotherapeutics Inc:

  • The MRQ is 1.976. The company is able to pay all its short-term debts. +1
  • The TTM is 1.555. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.976TTM1.555+0.420
TTM1.555YOY2.000-0.445
TTM1.5555Y1.486+0.069
5Y1.48610Y2.340-0.854
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9763.608-1.632
TTM1.5553.873-2.318
YOY2.0004.673-2.673
5Y1.4865.977-4.491
10Y2.3406.240-3.900
4.4.3.2. Quick Ratio

Measures if Protalix is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Protalix to the Biotechnology industry mean.
  • A Quick Ratio of 1.22 means the company can pay off $1.22 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Protalix Biotherapeutics Inc:

  • The MRQ is 1.222. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.360. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.222TTM1.360-0.138
TTM1.360YOY1.489-0.129
TTM1.3605Y1.452-0.092
5Y1.45210Y2.079-0.627
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2223.112-1.890
TTM1.3603.388-2.028
YOY1.4894.304-2.815
5Y1.4526.000-4.548
10Y2.0796.484-4.405
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Protalix Biotherapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Protalix assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Protalix to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.47 means that Protalix assets are financed with 47.3% credit (debt) and the remaining percentage (100% - 47.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Protalix Biotherapeutics Inc:

  • The MRQ is 0.473. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.608. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.473TTM0.608-0.135
TTM0.608YOY0.824-0.217
TTM0.6085Y1.069-0.461
5Y1.06910Y1.361-0.293
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4730.342+0.131
TTM0.6080.346+0.262
YOY0.8240.310+0.514
5Y1.0690.365+0.704
10Y1.3610.382+0.979
4.5.4.2. Debt to Equity Ratio

Measures if Protalix is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Protalix to the Biotechnology industry mean.
  • A Debt to Equity ratio of 89.8% means that company has $0.90 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Protalix Biotherapeutics Inc:

  • The MRQ is 0.898. The company is very able to pay all its debts with equity. +2
  • The TTM is 1.658. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ0.898TTM1.658-0.760
TTM1.658YOY16.897-15.239
TTM1.6585Y24.921-23.263
5Y24.92110Y13.458+11.463
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8980.393+0.505
TTM1.6580.432+1.226
YOY16.8970.379+16.518
5Y24.9210.451+24.470
10Y13.4580.494+12.964
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Protalix generates.

  • Above 15 is considered overpriced but always compare Protalix to the Biotechnology industry mean.
  • A PE ratio of 6.40 means the investor is paying $6.40 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Protalix Biotherapeutics Inc:

  • The EOD is 11.482. Based on the earnings, the company is underpriced. +1
  • The MRQ is 6.400. Based on the earnings, the company is cheap. +2
  • The TTM is -3.461. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD11.482MRQ6.400+5.082
MRQ6.400TTM-3.461+9.861
TTM-3.461YOY-8.928+5.467
TTM-3.4615Y13.771-17.232
5Y13.77110Y6.723+7.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD11.482-2.214+13.696
MRQ6.400-2.627+9.027
TTM-3.461-3.177-0.284
YOY-8.928-3.240-5.688
5Y13.771-6.006+19.777
10Y6.723-6.718+13.441
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Protalix Biotherapeutics Inc:

  • The EOD is 9.248. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 5.154. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 3.929. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD9.248MRQ5.154+4.093
MRQ5.154TTM3.929+1.225
TTM3.929YOY-4.214+8.143
TTM3.9295Y-4.199+8.129
5Y-4.19910Y-3.179-1.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD9.248-2.849+12.097
MRQ5.154-3.382+8.536
TTM3.929-3.731+7.660
YOY-4.214-4.479+0.265
5Y-4.199-8.046+3.847
10Y-3.179-9.219+6.040
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Protalix is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.55 means the investor is paying $2.55 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Protalix Biotherapeutics Inc:

  • The EOD is 4.582. Based on the equity, the company is fair priced.
  • The MRQ is 2.554. Based on the equity, the company is underpriced. +1
  • The TTM is 3.147. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.582MRQ2.554+2.028
MRQ2.554TTM3.147-0.593
TTM3.147YOY37.956-34.809
TTM3.1475Y30.630-27.483
5Y30.63010Y15.275+15.354
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.5821.969+2.613
MRQ2.5542.147+0.407
TTM3.1472.389+0.758
YOY37.9562.454+35.502
5Y30.6303.697+26.933
10Y15.2754.324+10.951
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Protalix Biotherapeutics Inc.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Income before Tax  -1,719-4,707-6,4261,693-4,7332,461-2,2726,1153,843
Net Income  -1,852-4,192-6,0441,449-4,5952,392-2,2035,4393,236
EBIT  -1,259-4,393-5,6521,309-4,3432,438-1,9056,0474,142
EBITDA  -954-4,385-5,3391,318-4,0212,435-1,5866,0574,471
Operating Income  -1,887-3,728-5,615759-4,8562,429-2,4276,4183,991
Net Income from Continuing Operations  -1,852-4,192-6,0441,449-4,5952,392-2,2035,4393,236



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets61,563
Total Liabilities29,126
Total Stockholder Equity32,437
 As reported
Total Liabilities 29,126
Total Stockholder Equity+ 32,437
Total Assets = 61,563

Assets

Total Assets61,563
Total Current Assets47,853
Long-term Assets13,710
Total Current Assets
Cash And Cash Equivalents 27,409
Net Receivables 2,195
Inventory 17,199
Other Current Assets 1,050
Total Current Assets  (as reported)47,853
Total Current Assets  (calculated)47,853
+/-0
Long-term Assets
Property Plant Equipment 10,293
Long-term Assets Other 561
Long-term Assets  (as reported)13,710
Long-term Assets  (calculated)10,854
+/- 2,856

Liabilities & Shareholders' Equity

Total Current Liabilities24,220
Long-term Liabilities4,906
Total Stockholder Equity32,437
Total Current Liabilities
Short-term Debt 1,508
Accounts payable 3,135
Other Current Liabilities 16,537
Total Current Liabilities  (as reported)24,220
Total Current Liabilities  (calculated)21,180
+/- 3,040
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt4,176
Long-term Liabilities  (as reported)4,906
Long-term Liabilities  (calculated)4,176
+/- 730
Total Stockholder Equity
Common Stock74
Retained Earnings -384,887
Other Stockholders Equity 417,324
Total Stockholder Equity (as reported)32,437
Total Stockholder Equity (calculated)32,511
+/- 74
Other
Capital Stock74
Cash and Short Term Investments 27,409
Common Stock Shares Outstanding 81,217
Liabilities and Stockholders Equity 61,563
Net Debt -21,725
Net Invested Capital 32,437
Net Working Capital 23,633
Property Plant and Equipment Gross 10,293
Short Long Term Debt Total 5,684



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-30
> Total Assets 
0
0
7,300
7,400
7,500
100
7,500
5,100
5,200
4,800
4,226
3,387
2,863
2,048
1,971
1,897
1,908
1,904
1,904
1,182
1,136
1,023
980
939
911
875
845
796
765
734
690
638
588
566
554
530
502
987
961
946
838
26,988
30,358
28,360
26,710
68,137
65,826
61,820
55,888
50,811
46,238
42,185
38,120
98,671
88,441
74,230
75,148
64,729
80,923
71,888
60,829
51,805
68,464
84,304
77,378
78,727
69,942
62,306
121,156
113,333
103,416
96,651
84,795
78,470
72,048
65,954
59,492
97,253
87,310
78,864
70,474
82,247
71,852
59,000
61,058
72,214
64,797
51,721
67,197
61,131
61,044
55,242
53,729
45,392
82,876
71,710
72,310
67,934
102,792
108,204
83,482
73,665
68,391
60,640
56,709
55,787
66,559
88,417
87,569
84,434
89,825
91,540
61,563
61,56391,54089,82584,43487,56988,41766,55955,78756,70960,64068,39173,66583,482108,204102,79267,93472,31071,71082,87645,39253,72955,24261,04461,13167,19751,72164,79772,21461,05859,00071,85282,24770,47478,86487,31097,25359,49265,95472,04878,47084,79596,651103,416113,333121,15662,30669,94278,72777,37884,30468,46451,80560,82971,88880,92364,72975,14874,23088,44198,67138,12042,18546,23850,81155,88861,82065,82668,13726,71028,36030,35826,9888389469619875025305545665886386907347657968458759119399801,0231,1361,1821,9041,9041,9081,8971,9712,0482,8633,3874,2264,8005,2005,1007,5001007,5007,4007,30000
   > Total Current Assets 
0
0
7,300
7,400
7,500
100
7,400
4,000
4,000
2,600
2,240
2,411
2,128
1,644
1,619
1,652
1,788
1,799
1,799
1,101
987
956
919
884
862
832
845
796
765
734
690
638
588
566
554
530
502
987
961
946
838
24,291
27,140
24,766
22,545
63,167
59,878
55,280
48,958
43,389
37,301
31,077
25,294
83,410
72,989
58,729
58,441
46,333
62,254
51,195
40,282
32,491
49,837
65,890
59,580
61,170
52,894
45,932
105,200
97,903
88,561
82,364
71,208
65,520
59,584
53,868
47,876
85,881
76,269
67,645
59,648
71,867
61,543
48,891
51,153
62,651
55,688
43,052
57,340
52,983
47,341
41,598
40,439
32,479
57,767
54,210
60,332
55,723
90,698
95,923
71,224
61,666
56,542
49,700
45,760
44,880
55,401
73,576
72,618
69,932
75,404
77,367
47,853
47,85377,36775,40469,93272,61873,57655,40144,88045,76049,70056,54261,66671,22495,92390,69855,72360,33254,21057,76732,47940,43941,59847,34152,98357,34043,05255,68862,65151,15348,89161,54371,86759,64867,64576,26985,88147,87653,86859,58465,52071,20882,36488,56197,903105,20045,93252,89461,17059,58065,89049,83732,49140,28251,19562,25446,33358,44158,72972,98983,41025,29431,07737,30143,38948,95855,28059,87863,16722,54524,76627,14024,2918389469619875025305545665886386907347657968458328628849199569871,1011,7991,7991,7881,6521,6191,6442,1282,4112,2402,6004,0004,0007,4001007,5007,4007,30000
       Cash And Cash Equivalents 
0
0
700
700
700
100
500
2,800
1,800
1,300
755
989
1,275
407
376
432
380
391
391
946
933
916
863
837
824
808
819
777
756
179
113
622
579
564
533
515
494
985
932
925
826
15,378
24,896
22,489
20,440
61,813
57,782
53,360
46,045
42,596
34,911
29,132
22,610
81,266
69,364
54,961
44,401
35,900
50,227
44,054
34,564
27,001
45,605
59,280
50,216
52,035
41,870
33,126
91,397
86,398
77,690
71,144
60,317
54,767
47,958
43,238
34,248
76,374
66,669
54,626
51,320
63,281
48,017
34,533
33,482
51,163
41,319
28,327
41,868
37,808
30,363
25,096
21,442
17,792
14,166
4,843
13,533
18,265
19,830
33,882
10,642
38,985
16,888
12,492
10,720
17,111
33,036
48,184
20,408
23,634
27,209
23,399
27,409
27,40923,39927,20923,63420,40848,18433,03617,11110,72012,49216,88838,98510,64233,88219,83018,26513,5334,84314,16617,79221,44225,09630,36337,80841,86828,32741,31951,16333,48234,53348,01763,28151,32054,62666,66976,37434,24843,23847,95854,76760,31771,14477,69086,39891,39733,12641,87052,03550,21659,28045,60527,00134,56444,05450,22735,90044,40154,96169,36481,26622,61029,13234,91142,59646,04553,36057,78261,81320,44022,48924,89615,3788269259329854945155335645796221131797567778198088248378639169339463913913804323764071,2759897551,3001,8002,80050010070070070000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
1,062
1,075
1,092
1,110
1,217
1,217
0
0
0
0
0
0
0
0
0
0
552
555
0
0
0
0
0
0
0
0
0
0
47
0
0
0
50
0
0
0
211
0
0
0
213
0
0
0
226
0
0
0
208
0
0
0
298
0
0
0
362
0
0
0
416
0
0
0
371
0
0
0
477
0
0
0
623
0
0
0
0
0
0
0
0
22,509
30,147
27,760
20,280
50,600
43,058
38,017
38,985
16,029
16,082
10,091
5,069
0
0
20,567
20,926
21,278
21,630
0
021,63021,27820,92620,567005,06910,09116,08216,02938,98538,01743,05850,60020,28027,76030,14722,509000000006230004770003710004160003620002980002080002260002130002110005000047000000000055555200000000001,2171,2171,1101,0921,0751,0620000000000000
       Net Receivables 
0
0
0
0
0
0
0
1,000
1,100
1,100
995
667
185
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,336
2,244
2,277
1,698
1,354
2,096
1,920
2,913
793
2,390
1,945
2,684
2,144
3,625
3,768
8,943
9,244
10,926
1,720
5,291
5,211
815
1,536
7,306
1,410
1,698
2,030
2,053
2,091
1,735
2,097
1,992
1,884
1,816
1,936
4,573
2,852
918
1,493
2,096
693
2,737
3,005
7,292
1,721
4,756
5,248
4,894
4,729
8,565
7,256
8,716
4,700
8,876
5,262
3,146
2,000
4,599
2,330
5,561
3,442
5,908
2,022
8,651
4,586
1,304
4,049
8,935
5,272
3,759
10,126
2,195
2,19510,1263,7595,2728,9354,0491,3044,5868,6512,0225,9083,4425,5612,3304,5992,0003,1465,2628,8764,7008,7167,2568,5654,7294,8945,2484,7561,7217,2923,0052,7376932,0961,4939182,8524,5731,9361,8161,8841,9922,0971,7352,0912,0532,0301,6981,4107,3061,5368155,2115,2911,72010,9269,2448,9433,7683,6252,1442,6841,9452,3907932,9131,9202,0961,3541,6982,2772,2441,33600000000000000000000000000001856679951,1001,1001,0000000000
       Other Current Assets 
0
0
6,600
6,700
6,800
0
6,900
200
1,100
200
490
755
668
175
169
129
298
191
191
154
54
40
0
47
38
24
25
19
9
2
22
15
9
2
21
15
8
2
30
21
12
7,577
0
0
407
235
0
0
0
176
0
0
0
208
3,625
3,768
8,943
354
10,926
4,884
5,291
5,211
3,154
4,045
7,306
3,048
3,553
3,585
4,173
809
2,609
1,988
2,069
1,417
2,931
2,326
2,716
888
2,945
5,135
1,045
1,428
3,484
4,081
2,689
663
2,594
2,499
2,619
863
1,706
2,248
2,756
698
2,728
2,893
2,612
2,096
1,754
3,013
2,274
1,285
1,123
2,597
1,736
536
758
1,708
1,125
1,055
812
1,493
1,050
1,0501,4938121,0551,1251,7087585361,7362,5971,1231,2852,2743,0131,7542,0962,6122,8932,7286982,7562,2481,7068632,6192,4992,5946632,6894,0813,4841,4281,0455,1352,9458882,7162,3262,9311,4172,0691,9882,6098094,1733,5853,5533,0487,3064,0453,1545,2115,2914,88410,9263548,9433,7683,625208000176000235407007,577122130281521291522291925243847040541541911912981291691756687554902001,1002006,90006,8006,7006,60000
   > Long-term Assets 
0
0
0
0
0
0
100
1,100
1,200
2,200
1,987
976
735
404
351
245
120
105
105
81
149
67
61
55
49
43
43
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,697
3,218
3,594
4,165
4,970
5,948
6,540
6,930
7,422
8,937
11,108
12,826
15,261
15,452
15,501
16,707
18,396
18,669
20,693
20,547
19,314
18,627
18,414
17,798
17,557
17,048
16,374
15,956
15,430
14,855
14,287
13,587
12,950
12,464
12,086
11,616
11,372
11,041
11,219
10,826
10,380
10,309
10,109
9,905
9,563
9,109
8,669
9,857
8,148
13,703
13,644
13,290
12,913
25,109
17,500
11,978
12,211
12,094
12,281
12,258
11,999
11,849
10,940
10,949
10,907
11,158
14,841
14,951
14,502
14,421
14,173
13,710
13,71014,17314,42114,50214,95114,84111,15810,90710,94910,94011,84911,99912,25812,28112,09412,21111,97817,50025,10912,91313,29013,64413,7038,1489,8578,6699,1099,5639,90510,10910,30910,38010,82611,21911,04111,37211,61612,08612,46412,95013,58714,28714,85515,43015,95616,37417,04817,55717,79818,41418,62719,31420,54720,69318,66918,39616,70715,50115,45215,26112,82611,1088,9377,4226,9306,5405,9484,9704,1653,5943,2182,69700000000000000434349556167149811051051202453514047359761,9872,2001,2001,100100000000
       Property Plant Equipment 
0
0
0
0
0
0
0
800
800
800
540
353
264
-108
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,404
2,898
3,248
3,763
4,506
5,404
5,914
6,273
6,841
8,383
10,458
12,112
14,537
14,674
14,734
15,841
17,454
17,654
18,944
18,510
18,271
17,507
17,342
16,664
16,310
15,705
15,001
14,340
13,711
13,098
12,438
11,846
11,282
10,839
10,392
9,957
9,744
9,310
9,480
9,140
8,703
8,472
8,158
7,986
7,676
7,311
6,940
6,628
6,390
11,902
11,773
11,337
10,950
10,725
10,470
10,339
10,412
10,318
10,397
10,310
9,922
9,797
9,537
9,531
9,640
9,906
10,443
10,599
10,882
10,660
10,339
10,293
10,29310,33910,66010,88210,59910,4439,9069,6409,5319,5379,7979,92210,31010,39710,31810,41210,33910,47010,72510,95011,33711,77311,9026,3906,6286,9407,3117,6767,9868,1588,4728,7039,1409,4809,3109,7449,95710,39210,83911,28211,84612,43813,09813,71114,34015,00115,70516,31016,66417,34217,50718,27118,51018,94417,65417,45415,84114,73414,67414,53712,11210,4588,3836,8416,2735,9145,4044,5063,7633,2482,8982,404000000000000000000000000000-1082643535408008008000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,505
5,025
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000005,02512,5050000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
352
245
120
105
86
81
149
67
61
55
49
43
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
293
320
346
402
464
544
626
657
581
554
650
714
724
778
767
866
942
1,015
1,749
2,037
1,043
1,120
1,072
1,134
1,247
1,343
1,373
1,616
1,719
1,757
1,849
1,741
1,668
1,625
1,694
1,659
1,628
1,731
1,739
1,686
1,677
1,837
1,951
1,919
1,887
1,798
1,729
1,779
1,758
1,801
1,871
1,953
1,963
1,879
2,005
1,639
7
1,776
1,884
1,948
2,077
2,052
1,403
1,418
1,267
1,252
4,398
4,352
0
0
0
0
00004,3524,3981,2521,2671,4181,4032,0522,0771,9481,8841,77671,6392,0051,8791,9631,9531,8711,8011,7581,7791,7291,7981,8871,9191,9511,8371,6771,6861,7391,7311,6281,6591,6941,6251,6681,7411,8491,7571,7191,6161,3731,3431,2471,1341,0721,1201,0432,0371,7491,0159428667677787247146505545816576265444644023463202930000000000000004349556167149818610512024535200000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
149
141
135
128
120
113
105
98
90
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000909810511312012813514114900000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
7,300
7,400
7,500
900
7,500
1,100
1,200
1,400
1,200
723
572
459
423
393
391
561
561
131
134
77
70
61
65
79
81
62
63
79
62
67
61
70
69
58
62
73
58
13
12
2,704
2,740
3,262
4,242
4,452
5,077
5,307
5,393
6,464
6,610
7,270
8,043
82,788
80,227
75,784
78,689
76,052
76,218
80,591
78,182
77,882
74,921
76,441
72,606
82,084
76,225
74,292
137,862
140,279
136,994
136,441
132,489
134,071
133,202
131,091
128,003
86,380
84,660
86,840
85,577
92,204
140,322
79,668
87,129
103,507
104,236
101,292
132,191
114,012
120,899
122,727
124,578
115,714
113,757
106,474
105,625
94,971
88,288
104,363
83,269
79,701
75,877
70,529
68,223
66,427
65,551
49,416
49,322
50,865
60,039
62,959
29,126
29,12662,95960,03950,86549,32249,41665,55166,42768,22370,52975,87779,70183,269104,36388,28894,971105,625106,474113,757115,714124,578122,727120,899114,012132,191101,292104,236103,50787,12979,668140,32292,20485,57786,84084,66086,380128,003131,091133,202134,071132,489136,441136,994140,279137,86274,29276,22582,08472,60676,44174,92177,88278,18280,59176,21876,05278,68975,78480,22782,7888,0437,2706,6106,4645,3935,3075,0774,4524,2423,2622,7402,70412135873625869706167627963628179656170771341315615613913934234595727231,2001,4001,2001,1007,5009007,5007,4007,30000
   > Total Current Liabilities 
0
0
0
100
100
600
100
1,100
1,200
1,400
1,159
682
536
459
423
393
391
561
561
131
134
77
70
61
65
79
81
62
63
79
62
67
61
70
69
58
62
73
58
13
12
2,268
2,230
2,699
3,613
3,762
4,205
4,340
4,399
5,527
5,693
6,214
6,900
21,530
19,816
15,746
20,487
18,903
20,130
20,282
18,314
18,693
17,724
21,332
20,435
25,755
24,408
26,628
25,226
26,696
26,781
27,179
24,384
26,210
26,549
25,519
22,853
11,235
9,279
11,460
10,333
66,212
20,289
19,116
26,591
22,752
21,499
15,072
14,551
25,353
27,036
25,993
33,319
40,175
47,628
42,415
43,895
86,474
80,861
96,247
42,764
33,176
35,331
30,960
34,302
32,429
31,515
23,109
43,359
45,530
54,828
57,972
24,220
24,22057,97254,82845,53043,35923,10931,51532,42934,30230,96035,33133,17642,76496,24780,86186,47443,89542,41547,62840,17533,31925,99327,03625,35314,55115,07221,49922,75226,59119,11620,28966,21210,33311,4609,27911,23522,85325,51926,54926,21024,38427,17926,78126,69625,22626,62824,40825,75520,43521,33217,72418,69318,31420,28220,13018,90320,48715,74619,81621,5306,9006,2145,6935,5274,3994,3404,2053,7623,6132,6992,2302,26812135873625869706167627963628179656170771341315615613913934234595366821,1591,4001,2001,100100600100100000
       Short-term Debt 
0
0
0
0
0
500
0
0
0
0
17
17
21
58
58
58
23
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,681
12,572
0
0
0
0
0
0
0
67,048
0
0
0
67,351
0
0
0
5,534
4,757
6,844
72,430
53,872
53,872
57,881
5,911
5,921
5,930
31,885
61,780
0
1,257
1,227
1,222
5,440
5,427
5,446
5,477
59,933
56,758
57,590
4,474
1,207
1,243
1,083
1,000
1,118
1,149
1,260
22,818
23,069
21,873
23,320
1,508
1,50823,32021,87323,06922,8181,2601,1491,1181,0001,0831,2431,2074,47457,59056,75859,9335,4775,4465,4275,4401,2221,2271,257061,78031,8855,9305,9215,91157,88153,87253,87272,4306,8444,7575,53400067,35100067,048000000012,57212,681000000000000000000000000000000000000000000023585858211717000050000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
67,048
0
0
0
67,351
0
0
0
72,097
53,872
72,000
72,430
53,872
117,505
57,881
5,911
5,921
5,930
46,742
0
0
1,257
0
0
4,301
4,301
4,301
4,301
58,513
55,372
56,355
3,239
0
0
0
0
0
0
0
20,192
20,251
20,420
20,420
0
020,42020,42020,25120,19200000003,23956,35555,37258,5134,3014,3014,3014,301001,2570046,7425,9305,9215,91157,881117,50553,87272,43072,00053,87272,09700067,35100067,048000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
500
532
398
373
328
291
262
295
84
487
58
60
77
70
61
65
79
81
62
63
79
62
67
4
4
4
0
0
0
0
13
12
892
788
867
1,359
899
1,057
1,714
2,067
2,235
1,707
1,982
1,891
3,406
5,429
4,431
5,667
6,272
7,533
5,847
12,681
12,572
4,568
4,512
4,427
5,267
3,762
3,944
3,313
5,254
4,639
3,592
3,578
3,951
5,195
4,275
4,057
3,629
3,890
3,819
3,989
4,007
5,999
7,852
8,691
7,521
4,872
6,001
4,388
5,211
5,870
6,728
7,755
6,495
9,430
6,707
8,351
7,221
6,376
6,128
8,436
6,986
7,873
6,991
5,639
5,862
5,105
3,304
3,114
4,320
3,146
4,064
3,135
3,1354,0643,1464,3203,1143,3045,1055,8625,6396,9917,8736,9868,4366,1286,3767,2218,3516,7079,4306,4957,7556,7285,8705,2114,3886,0014,8727,5218,6917,8525,9994,0073,9893,8193,8903,6294,0574,2755,1953,9513,5783,5924,6395,2543,3133,9443,7625,2674,4274,5124,56812,57212,6815,8477,5336,2725,6674,4315,4293,4061,8911,9821,7072,2352,0671,7141,0578991,359867788892121300004446762796362817965617077605848784295262291328373398532500000000000
       Other Current Liabilities 
0
0
0
100
100
100
100
1,100
1,200
900
610
267
141
74
74
74
74
476
74
74
74
73
66
57
61
4
77
58
59
75
57
63
57
66
65
58
62
73
58
0
0
1,376
1,442
1,832
2,254
2,863
3,148
2,626
2,332
3,292
3,986
4,232
5,009
13,561
9,824
6,752
15,924
8,068
8,034
8,289
12,681
12,572
8,298
11,962
11,444
11,051
12,055
13,681
12,400
12,073
14,533
16,305
14,186
15,496
14,282
14,316
11,946
1,568
128
293
5,840
7,496
12,365
9,339
11,989
-17,541
-18,333
-22,814
-51,617
10,274
10,480
10,496
12,730
11,905
13,757
11,910
13,347
13,926
15,167
14,420
14,694
16,433
14,414
12,663
12,870
12,271
13,471
18,545
14,170
15,265
15,894
15,017
16,537
16,53715,01715,89415,26514,17018,54513,47112,27112,87012,66314,41416,43314,69414,42015,16713,92613,34711,91013,75711,90512,73010,49610,48010,274-51,617-22,814-18,333-17,54111,9899,33912,3657,4965,8402931281,56811,94614,31614,28215,49614,18616,30514,53312,07312,40013,68112,05511,05111,44411,9628,29812,57212,6818,2898,0348,06815,9246,7529,82413,5615,0094,2323,9863,2922,3322,6263,1482,8632,2541,8321,4421,3760058736258656657635775595877461576673747474476747474741412676109001,2001,100100100100100000
   > Long-term Liabilities 
0
0
7,300
7,300
7,400
300
7,400
100
100
0
41
41
37
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
300
0
0
0
436
510
563
629
690
872
967
994
937
917
1,056
1,143
61,258
60,411
60,038
58,202
57,149
56,088
60,309
59,868
59,189
57,197
55,109
52,171
56,329
51,817
47,664
112,636
113,583
110,213
109,262
108,105
107,861
106,653
105,572
105,150
75,145
75,381
75,380
75,244
25,992
120,033
60,552
60,538
80,755
82,737
86,220
117,640
88,659
93,863
96,734
91,259
75,539
66,129
64,059
61,730
8,497
7,427
8,116
40,505
46,525
40,546
39,569
33,921
33,998
34,036
26,307
5,963
5,335
5,211
4,987
4,906
4,9064,9875,2115,3355,96326,30734,03633,99833,92139,56940,54646,52540,5058,1167,4278,49761,73064,05966,12975,53991,25996,73493,86388,659117,64086,22082,73780,75560,53860,552120,03325,99275,24475,38075,38175,145105,150105,572106,653107,861108,105109,262110,213113,583112,63647,66451,81756,32952,17155,10957,19759,18959,86860,30956,08857,14958,20260,03860,41161,2581,1431,05691793799496787269062956351043600030000000000000000000000000037414101001007,4003007,4007,3007,30000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,452
4,738
0
0
4,680
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
47,320
0
48,670
49,401
0
0
0
0
0
0
0
0
0
27,887
27,962
28,033
28,111
28,187
28,267
20,132
0
0
0
0
0
0000020,13228,26728,18728,11128,03327,96227,88700000000049,40148,670047,3200000000000000000000000004,680004,7384,45200000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
149
141
135
128
120
113
105
98
90
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000909810511312012813514114900000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
436
510
563
629
690
872
967
994
937
917
1,056
1,143
61,258
60,411
60,038
58,202
57,149
56,088
60,309
59,868
59,189
57,197
55,109
52,171
56,329
51,817
47,664
45,692
46,535
43,062
42,007
40,746
40,397
39,087
37,902
37,376
3,048
3,174
3,062
2,814
2,348
2,528
2,671
2,612
30,187
31,457
34,220
35,879
36,393
35,405
37,419
31,192
20,054
9,871
6,911
3,667
4,030
3,108
3,609
8,248
14,262
8,391
7,643
1,779
1,642
0
0
0
0
0
0
0
00000001,6421,7797,6438,39114,2628,2483,6093,1084,0303,6676,9119,87120,05431,19237,41935,40536,39335,87934,22031,45730,1872,6122,6712,5282,3482,8143,0623,1743,04837,37637,90239,08740,39740,74642,00743,06246,53545,69247,66451,81756,32952,17155,10957,19759,18959,86860,30956,08857,14958,20260,03860,41161,2581,1431,05691793799496787269062956351043600000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
54,052
53,425
50,923
49,781
48,640
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,450
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000001,45000000000000000000000000048,64049,78150,92353,42554,05200000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
0
0
-700
0
4,000
4,000
3,400
3,026
2,664
2,291
1,589
1,548
1,504
1,516
1,344
1,344
1,050
1,002
946
910
878
846
796
764
734
702
655
629
570
527
495
485
472
440
914
903
932
825
24,284
27,618
25,098
22,468
63,685
60,749
56,513
50,495
44,347
39,628
34,915
30,077
15,883
8,214
-1,554
-3,541
-11,323
4,705
-8,703
-17,353
-26,077
-6,457
7,863
4,772
-3,357
-6,283
-11,986
-16,706
-26,946
-33,578
-39,790
-47,694
-55,601
-61,154
-65,137
-68,511
10,873
2,650
-7,976
-15,103
-9,957
-68,470
-20,668
-26,071
-31,293
-39,439
-49,571
-64,994
-52,881
-59,855
-67,485
-70,849
-70,322
-30,881
-34,764
-33,315
-27,037
14,504
3,841
213
-6,036
-7,486
-9,889
-11,514
-10,640
1,008
39,001
38,247
33,569
29,786
28,581
32,437
32,43728,58129,78633,56938,24739,0011,008-10,640-11,514-9,889-7,486-6,0362133,84114,504-27,037-33,315-34,764-30,881-70,322-70,849-67,485-59,855-52,881-64,994-49,571-39,439-31,293-26,071-20,668-68,470-9,957-15,103-7,9762,65010,873-68,511-65,137-61,154-55,601-47,694-39,790-33,578-26,946-16,706-11,986-6,283-3,3574,7727,863-6,457-26,077-17,353-8,7034,705-11,323-3,541-1,5548,21415,88330,07734,91539,62844,34750,49556,51360,74963,68522,46825,09827,61824,2848259329039144404724854955275706296557027347647968468789109461,0021,0501,3441,3441,5161,5041,5481,5892,2912,6643,0263,4004,0004,0000-70000000
   Common Stock
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
62
66
66
66
76
76
76
76
76
76
76
77
81
81
81
81
81
86
86
86
86
91
92
93
93
94
94
94
93
94
94
94
94
94
94
94
100
100
100
100
124
125
129
134
144
146
148
148
148
148
148
148
15
33
33
33
35
46
46
46
46
46
49
50
54
62
72
73
73
73
73
74
747373737372625450494646464646353333331514814814814814814814614413412912512410010010010094949494949494939494949393929186868686818181818177767676767676766666666211110000000000000000000000000110000000000
   Retained Earnings Total Equity0000000000000000000-340,829000-322,553000-297,932000-212,656000-183,291000-241,328000-211,385000-183,595000-171,9770000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
-1,000
-800
-800
-355
-241
-145
-87
-28
0
0
0
-108
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
355
-977
-977
-977
-1,620
-1,620
-1,620
-1,620
-2,911
-80,193
0
0
-4,695
0
0
0
-7,589
0
0
0
-11,148
0
0
0
-14,786
0
0
0
-18,319
-18,319
0
0
-21,454
-21,454
0
0
-23,803
-23,803
0
0
-25,601
-25,601
0
0
-27,465
0
0
0
-29,116
-29,116
0
0
-30,704
-30,704
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000-30,704-30,70400-29,116-29,116000-27,46500-25,601-25,60100-23,803-23,80300-21,454-21,45400-18,319-18,319000-14,786000-11,148000-7,589000-4,69500-80,193-2,911-1,620-1,620-1,620-1,620-977-977-9773550000000000000000000000-108000-28-87-145-241-355-800-800-1,0000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
145,814
0
0
0
180,145
0
0
0
184,346
0
0
0
185,633
0
0
0
194,064
0
0
0
202,575
0
0
0
266,495
0
0
0
269,524
0
0
0
270,492
0
0
0
0
0
0
0
368,852
369,688
372,616
374,557
379,167
393,938
412,582
413,679
0
0
0
0
0000413,679412,582393,938379,167374,557372,616369,688368,8520000000270,492000269,524000266,495000202,575000194,064000185,633000184,346000180,145000145,8140000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
6,000
5,800
6,100
5,515
5,069
4,869
4,549
4,441
4,410
4,410
0
4,301
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,233
4,727
4,727
4,727
4,727
44,379
52,491
59,125
61,241
108,222
110,399
110,392
110,870
122,192
119,745
34,915
30,077
126,947
122,538
122,811
123,298
131,633
145,119
145,400
145,625
156,962
171,333
176,010
178,397
194,931
181,539
182,673
183,700
202,665
185,058
184,965
185,071
207,087
186,052
187,140
187,586
217,867
194,439
194,666
194,829
228,176
203,209
250,557
256,586
293,960
263,750
268,907
269,028
298,640
269,814
269,814
270,123
301,196
308,248
308,515
314,401
320,280
367,285
367,863
368,434
368,852
369,688
372,616
374,557
379,167
393,938
412,582
413,679
415,045
415,633
416,631
417,324
417,324416,631415,633415,045413,679412,582393,938379,167374,557372,616369,688368,852368,434367,863367,285320,280314,401308,515308,248301,196270,123269,814269,814298,640269,028268,907263,750293,960256,586250,557203,209228,176194,829194,666194,439217,867187,586187,140186,052207,087185,071184,965185,058202,665183,700182,673181,539194,931178,397176,010171,333156,962145,625145,400145,119131,633123,298122,811122,538126,94730,07734,915119,745122,192110,870110,392110,399108,22261,24159,12552,49144,3794,7274,7274,7274,7274,2334,2334,2334,2334,2334,2334,2334,2334,2334,2334,2334,2334,2334,2334,2334,2334,2334,2334,30104,4104,4104,4414,5494,8695,0695,5156,1005,8006,0000000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue65,494
Cost of Revenue-22,982
Gross Profit42,51242,512
 
Operating Income (+$)
Gross Profit42,512
Operating Expense-32,052
Operating Income10,46010,460
 
Operating Expense (+$)
Research Development17,093
Selling General Administrative25,459
Selling And Marketing Expenses40,418
Operating Expense32,05282,970
 
Net Interest Income (+$)
Interest Income1,286
Interest Expense-3,180
Other Finance Cost-0
Net Interest Income-1,894
 
Pretax Income (+$)
Operating Income10,460
Net Interest Income-1,894
Other Non-Operating Income Expenses0
Income Before Tax (EBT)8,56612,354
EBIT - interestExpense = 7,280
8,566
11,492
Interest Expense3,180
Earnings Before Interest and Taxes (EBIT)10,46011,746
Earnings Before Interest and Taxes (EBITDA)11,651
 
After tax Income (+$)
Income Before Tax8,566
Tax Provision-254
Net Income From Continuing Ops8,3128,312
Net Income8,312
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses55,034
Total Other Income/Expenses Net-1,8941,894
 

Technical Analysis of Protalix
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Protalix. The general trend of Protalix is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Protalix's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Protalix Biotherapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1.83 < 1.83 < 1.8301.

The bearish price targets are: 1.6 > 1.5701 > 1.54.

Tweet this
Protalix Biotherapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Protalix Biotherapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Protalix Biotherapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Protalix Biotherapeutics Inc. The current macd is 0.07783454.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Protalix price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Protalix. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Protalix price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Protalix Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartProtalix Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Protalix Biotherapeutics Inc. The current adx is 32.09.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Protalix shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Protalix Biotherapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Protalix Biotherapeutics Inc. The current sar is 1.6046.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Protalix Biotherapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Protalix Biotherapeutics Inc. The current rsi is 67.28. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Protalix Biotherapeutics Inc Daily Relative Strength Index (RSI) ChartProtalix Biotherapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Protalix Biotherapeutics Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Protalix price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Protalix Biotherapeutics Inc Daily Stochastic Oscillator ChartProtalix Biotherapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Protalix Biotherapeutics Inc. The current cci is 89.24.

Protalix Biotherapeutics Inc Daily Commodity Channel Index (CCI) ChartProtalix Biotherapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Protalix Biotherapeutics Inc. The current cmo is 36.76.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Protalix Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartProtalix Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Protalix Biotherapeutics Inc. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Protalix Biotherapeutics Inc Daily Williams %R ChartProtalix Biotherapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Protalix Biotherapeutics Inc.

Protalix Biotherapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Protalix Biotherapeutics Inc. The current atr is 0.08636773.

Protalix Biotherapeutics Inc Daily Average True Range (ATR) ChartProtalix Biotherapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Protalix Biotherapeutics Inc. The current obv is 9,092,124.

Protalix Biotherapeutics Inc Daily On-Balance Volume (OBV) ChartProtalix Biotherapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Protalix Biotherapeutics Inc. The current mfi is 47.83.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Protalix Biotherapeutics Inc Daily Money Flow Index (MFI) ChartProtalix Biotherapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Protalix Biotherapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-23MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-12-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Protalix Biotherapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Protalix Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5067.275
Ma 20Greater thanMa 501.740
Ma 50Greater thanMa 1001.484
Ma 100Greater thanMa 2001.254
OpenGreater thanClose1.780
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Protalix with someone you think should read this too:
  • Are you bullish or bearish on Protalix? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Protalix? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Protalix Biotherapeutics Inc

I send you an email if I find something interesting about Protalix Biotherapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Protalix Biotherapeutics Inc.

Receive notifications about Protalix Biotherapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.